Tesamorelin, CJC-1295 and ipamorelin are all studied in growth-hormone axis research, and are often listed side by side as if they were three versions of the same thing. They are not. Two act on the GHRH receptor and one acts on a completely different receptor – which is precisely why two of them are commonly studied in combination rather than as substitutes.
- Tesamorelin
- GHRH analog
- CJC-1295
- Long-acting GHRH analog
- Ipamorelin
- Ghrelin-receptor (GHS-R) secretagogue
- Why blended
- Different receptors, same axis
The short answer
Tesamorelin and CJC-1295 are both GHRH analogs: they resemble growth-hormone-releasing hormone and act at the GHRH receptor. Ipamorelin is a growth-hormone secretagogue that acts at the ghrelin receptor (GHS-R) instead. Because a GHRH analog and a GHS-R secretagogue press different buttons on the same axis, they are frequently studied together – which is why the CJC-1295 + ipamorelin blend exists as a single research listing.
| Tesamorelin | CJC-1295 | Ipamorelin | |
|---|---|---|---|
| Receptor | GHRH receptor | GHRH receptor | Ghrelin receptor (GHS-R) |
| Class | GHRH analog | GHRH analog | Secretagogue (GHRP) |
| Duration profile | Short-acting | Long-acting | Short-acting |
| Selectivity note | GHRH-selective | GHRH-selective | Selective for GH release |
| Human trial data | Most extensive of the three | Limited | Limited |
GHRH analogs: tesamorelin and CJC-1295
Both tesamorelin and CJC-1295 work one step upstream of growth hormone itself. Instead of supplying growth hormone directly, they resemble the releasing hormone that signals the pituitary, and published research studies them at that receptor. The practical difference between the two is duration: CJC-1295 was designed for an extended half-life, while tesamorelin has a shorter profile and, of the three compounds on this page, the most extensive published human trial record.
Ipamorelin: a different receptor entirely
Ipamorelin is not a GHRH analog. It acts at the ghrelin receptor, GHS-R, which is a separate pathway into the same axis. Published work describes it as selective in the sense that it stimulates growth hormone release without the broader hormonal cross-reactivity seen with some earlier secretagogues. Because it engages a different receptor from the GHRH analogs, it is not a substitute for them.
Why CJC-1295 and ipamorelin are blended
The CJC-1295 + ipamorelin listing exists because the two engage different receptors on the same axis – a long-acting GHRH analog and a GHS-R secretagogue. Research interest in the pairing comes from that complementarity rather than from additive potency. Tesamorelin, being a GHRH analog itself, occupies the same receptor as CJC-1295 and so is not blended with it.
What the evidence supports
Tesamorelin has the strongest published human trial record of the three. CJC-1295 and ipamorelin have more limited published human data, with the bulk of their literature mechanistic or preclinical. Any research design assuming equivalence across the three is not supported by the published record – they differ in receptor, duration and evidence depth simultaneously.
All compounds referenced here are supplied as analytical-grade reference materials for in-vitro and laboratory research only. Nothing on this page is a recommendation for human or veterinary use, and no comparison below should be read as ranking these materials for any personal outcome.
Studies cited
- Tesamorelin — overview (, 2012)
- Tesamorelin in HIV patients — clinical study (AIDS (London, England), 2024)
- Tesamorelin — drug profile (Nature reviews. Drug discovery, 2011)
- Prolonged stimulation of growth hormone and IGF-I secretion by CJC-1295, a long-acting GHRH analog, in healthy adults (The Journal of clinical endocrinology and metabolism, 2006)
- Pulsatile secretion of growth hormone persists during continuous stimulation by CJC-1295 (The Journal of clinical endocrinology and metabolism, 2006)
- Once-daily CJC-1295, a long-acting GHRH analog, normalizes growth in the GHRH-knockout mouse (American journal of physiology. Endocrinology and metabolism, 2006)
- Ipamorelin, the first selective growth hormone secretagogue (European Journal of Endocrinology, 1998)
- Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats (Growth Hormone & IGF Research, 1999)
- Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers (Pharmaceutical Research, 1999)
Questions
What is the difference between a GHRH analog and a secretagogue?
A GHRH analog such as tesamorelin or CJC-1295 resembles growth-hormone-releasing hormone and acts at the GHRH receptor. A secretagogue such as ipamorelin acts at the ghrelin receptor, GHS-R. Both engage the growth-hormone axis, but through different receptors.
Why are CJC-1295 and ipamorelin sold as a blend?
CJC-1295 and ipamorelin engage different receptors on the same axis – a long-acting GHRH analog and a ghrelin-receptor secretagogue. Research interest in the combination comes from that complementarity, which is why they appear as a single blended research listing.
Is tesamorelin the same as CJC-1295?
Both tesamorelin and CJC-1295 are GHRH analogs acting at the same receptor, but they differ in duration profile and in evidence depth. CJC-1295 was designed for an extended half-life; tesamorelin is shorter-acting and has the more extensive published human trial record.
Which of these has the most published human data?
Tesamorelin has the most extensive published human trial record of the three. CJC-1295 and ipamorelin have more limited human data, with most of their literature mechanistic or preclinical.
For laboratory research and educational purposes only. Not medical advice. The materials discussed are not for human or animal consumption and have not been evaluated by the FDA.